Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1.

Molecular therapy. Oncology·2026

Same author

Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses.

Molecular cancer therapeutics·2026

Same author

Triple-Mutated HSV-1 Expressing Soluble B7-1 Plus CTLA-4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer.

Cancer science·2026

Same author

MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy.

Molecular therapy. Oncology·2026

Same author

Multihit Somatic Mosaicism of <i>TP53</i> Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

JCO precision oncology·2025

Same author

Epithelial-Mesenchymal Transition and Genetically Driven Early Tumor Seedings in Extraneural Metastasis of Glioblastoma.

Cancer science·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Active immunotherapy: oncolytic virus therapy using HSV-1.

¹Department of Neurosurgery, The University of Tokyo, Tokyo, Japan. toudou-nsu@umin.ac.jp

Advances in Experimental Medicine and Biology

|May 29, 2012

Summary

This summary is machine-generated.

Genetically engineered herpes simplex virus type 1 (HSV-1), G47Δ, shows promise for glioma treatment. This oncolytic virus replicates in tumors, induces antitumor immunity, and functions as an in situ tumor vaccination.

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Experiment Videos

Last Updated: May 22, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Area of Science:

Oncolytic virotherapy
Cancer immunotherapy
Neuro-oncology

Background:

Conditionally replicating herpes simplex viruses type 1 (HSV-1) are investigated as glioma therapeutics.
HSV-1 exhibits in situ replication, tumor cell spread, and direct cytocidal effects.
Oncolytic activity of HSV-1 can induce specific antitumor immunity.

Purpose of the Study:

To evaluate G47Δ, a triple-mutated HSV-1, for enhanced tumor cell replication, antitumor immunity induction, and safety.
To explore the potential of armed HSV-1 with immunomodulatory transgenes for augmenting therapeutic efficacy.
To position HSV-1 oncolytic virotherapy as a potential treatment and in situ tumor vaccination strategy for glioma.

Main Methods:

Utilized genetically engineered herpes simplex virus type 1 (G47Δ) with triple mutations.
Investigated in vitro and in vivo characteristics of G47Δ, including replication, spread, and immunogenicity.
Preclinical studies involved "arming" HSV-1 with transgenes encoding immunomodulatory molecules like interleukin 12.

Main Results:

G47Δ demonstrated augmented viral replication in tumor cells.
Strong induction of antitumor immunity was observed.
Enhanced safety profile in normal tissues was noted.
Preclinical studies showed "arming" HSV-1 with transgenes significantly augmented therapeutic efficacy.

Conclusions:

G47Δ is a promising therapeutic agent for glioma with enhanced oncolytic and immunomodulatory properties.
HSV-1's capacity for transgene incorporation allows for "arming" to improve efficacy.
Oncolytic HSV-1 therapy offers a potential treatment strategy for glioma, acting as an in situ tumor vaccination.